Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study co-authored by the Department of Psychiatry's Prof Andrea Cipriani shows that of all available drugs, methylphenidate should be first option for short-term treatment in children.

Of the drugs available for attention-deficit hyperactivity disorder (ADHD), the most effective and safe for short-term treatment is methylphenidate for children, and amphetamines for adults, according to the most comprehensive evidence yet from a network meta-analysis and systematic review comparing the effectiveness and safety of seven ADHD drugs against placebo, published in The Lancet Psychiatry journal.


The study, which was led by Prof Andrea Cipriani, compared the effectiveness and side effects of amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with each other or with placebo over 12 weeks of treatment. However, more research to confirm longer term effects of ADHD medications is urgently needed.

Although they are commonly prescribed for people with ADHD, the study did not include antipsychotic drugs or antidepressants as they do not treat ADHD core symptoms. The study also does not include psychological therapies used for ADHD, but the authors say that these should be regularly discussed with people with ADHD and their family members or carers, and possibly offered before ADHD medications, if appropriate, especially for children and adolescents. 

 

Read more

Similar stories

New Analysis Challenges Guidelines on Treating Anorexia Nervosa

Research Highlights

A new analysis, published in The Lancet Psychiatry, has shown a lack of strong evidence to support current guidance on psychological therapies for treating anorexia nervosa over expert treatment as usual.

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Research Highlights

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

How the brain reorganises old memories when new ones are made

Research Highlights

Researchers have discovered that the arrangement of existing memories in the brain is altered when we embed new memories

Improving Experiences of People with Serious Mental Health Problems

Research Highlights

A project led by Professor Kam Bhui and Dr Roisin Mooney, University of Oxford, will focus on reducing the number of people admitted or readmitted to compulsory care under the Mental Health Act. This is one of four new research projects funded by the National Institute for Health Research (NIHR) with the aim to improve patient experiences and outcomes under the Mental Health Act.

Potential New Target to Prevent or Delay Dementia

Research Highlights

New study shows targeting arterial stiffening earlier in a person’s lifespan could provide cognitive benefits in older age and may help to delay the onset of dementia.

Investigating New Treatment for Schizophrenia

Research Highlights Strategic Developments

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim has been announced to investigate a new drug target for the treatment of schizophrenia.